AstraZeneca, Amgen roll up a 'breakthrough' at the FDA in hot pursuit of a potential game changer in asthma
By this point, the novelty of the FDA’s breakthrough therapy designation has largely been worn away by a drumbeat of announcements for new additions to the program. But AstraZeneca and Amgen just landed one that deserves a closer look.
Regulators have handed the big league partners VIP status for a severe asthma drug called tezepelumab. As always, BTD gives them ready access to FDA insiders who are now pledged to help push this through to a speedy conclusion. And we know now that that promise is worth something.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.